PT  - JOURNAL ARTICLE
AU  - Lyski, Zoe L.
AU  - Kim, Myung S.
AU  - Xthona Lee, David
AU  - Raué, Hans-Peter
AU  - Raghunathan, Vikram
AU  - Griffin, Janet
AU  - Ryan, Debbie
AU  - Brunton, Amanda E.
AU  - Curlin, Marcel E.
AU  - Slifka, Mark K.
AU  - Messer, William B.
AU  - Spurgeon, Stephen E.
TI  - Cellular and humoral Immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia
AID  - 10.1101/2021.11.04.21265948
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.04.21265948
4099  - http://medrxiv.org/content/early/2021/11/05/2021.11.04.21265948.short
4100  - http://medrxiv.org/content/early/2021/11/05/2021.11.04.21265948.full
AB  - Chronic Lymphocytic Leukemia (CLL) is predominantly a B-lymphocyte leukemia associated with immune defects that are often exacerbated by CLL directed therapies. SARS-CoV-2 infection poses a significant risk of illness or mortality to CLL patients, and while SARS-CoV-2 vaccines are highly effective in immunocompetent individuals, efficacy varies substantially in immunocompromised patients, including those with CLL. To date, studies of COVID-19 vaccine immune responses in immunocompromised hosts have largely relied on semi-quantitative antibody titers that only partially characterize vaccine-elicited immune responses and do not measure B or T-cell specific responses that may also play a protective role in vaccinees. Here, we report RBD-specific antibody as well as B-cell and T-cell responses in an observational cohort of sixteen CLL subjects who received mRNA vaccination against SARS-CoV-2, finding a strong association between CLL treatment and vaccine immunogenicity, with important implications for vaccination timing in the context of CLL treatment or recovery from prior treatment.Competing Interest Statement(SES): Consulting: Velos Bio, Karyopharm, Genentech; Janssen, Pharmacyclics; Research: Acerta Pharma, Astrazeneca, Beigene, Bristol Myers Squibb, Genentech, Gilead Sciences, Ionis, Janssen. All other authors, have no declarations of interest.Funding StatementThis work was funded in part by National Institute of Allergy and Infectious Diseases NIAID 1R01AI145835 (WBM), by US National Institute of Health grant P51 OD011092 (MKS), and endowed funds from the Knight Cancer Institute's Scholar Award for Leukemia and Lymphoma Research (SES).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was approved by the Oregon Health and Science University Institutional Review Board (OHSU IRB# 21230)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript